FDAnews
www.fdanews.com/articles/81949-tanox-reports-results-from-phase-ii-trial-of-tnx-355

TANOX REPORTS RESULTS FROM PHASE II TRIAL OF TNX-355

October 26, 2005

Tanox has reported positive Phase II clinical results of its novel HIV drug candidate, TNX-355. The 24-week results of the study show that TNX-355 at the 10 mg/kg dose, when given in combination with optimized background therapy (OBT), produced a considerably greater reduction in viral load in HIV-infected patients than did placebo in combination with OBT.

TNX-355 was well-tolerated, with no serious adverse events related to the drug. The study met its primary endpoint with TNX-355 plus OBT demonstrating a statistically significant reduction in viral load -- the level of HIV in the bloodstream -- compared to placebo plus OBT at Week 24.